|
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
|
|
Washington, D.C. 20549
|
FORM 8-K
|
CURRENT REPORT
|
Pursuant to Section 13 or 15(d)
|
of The Securities Exchange Act of 1934
|
Date of Report
(Date of earliest event reported):
May 7,
2020
|
MONOPAR THERAPEUTICS INC.
|
(Exact
name of registrant as specified in its charter)
|
Delaware
|
001-39070
|
32-0463781
|
(State
or other jurisdiction of incorporation)
|
(Commission
File Number)
|
(I.R.S.
Employer Identification No.)
|
1000 Skokie Blvd., Suite 350, Wilmette, IL
(Address
of principal executive offices)
|
|
60091
(Zip
Code)
|
|
(847) 388-0349
|
|
|
Registrant’s
telephone number, including area code
|
|
|
N/A
|
|
|
(Former
name or former address, if changed since last report)
|
|
|
Securities registered pursuant to Section 12(b) of the
Act:
|
|
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
Common
Stock, $0.001 par value
|
|
MNPR
|
|
The
Nasdaq Stock Market LLC
(Nasdaq
Capital Market)
|
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Indicate by check
mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (§ 230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of
1934 (§ 240.12b-2 of this chapter).
Emerging growth
company ☒
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☒
Item 2.02
Results of Operations and Financial
Condition.
On
May 7, 2020, Monopar Therapeutics Inc. issued a press release
announcing its financial results for the first quarter ended March
31, 2020. A copy of this press release is attached hereto as
Exhibit 99.1.
The
information in this Item 2.02 and the exhibit hereto are being
furnished and shall not be deemed to be “filed” for
purposes of Section 18 of the Securities Exchange Act of 1934,
as amended (the “Exchange Act”), or otherwise subject
to the liability of that section, nor shall they be deemed
incorporated by reference in any filing under the Securities Act of
1933, as amended, or the Exchange Act, except as expressly set
forth by specific reference in such a filing.
Item
9.01 Financial Statements and Exhibits
Exhibit
No.
|
|
Description
|
99.1
|
|
Press Release Dated May 7,
2020
|
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
Monopar
Therapeutics Inc.
|
|
|
|
|
|
Date: May 7,
2020
|
By:
|
/s/
Kim R.
Tsuchimoto
|
|
|
|
Name: Kim R.
Tsuchimoto
|
|
|
|
Title:
Chief
Financial Officer
|
|